Volume 122, Issue 3 pp. 410-417

Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease

R. S. Weening

R. S. Weening

Emma Children's Hospital and

Central Laboratory of the Netherlands Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam,

Search for more papers by this author
M. De Boer

M. De Boer

Central Laboratory of the Netherlands Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam,

Search for more papers by this author
T. W. Kuijpers

T. W. Kuijpers

Emma Children's Hospital and

Search for more papers by this author
V. M. E. Neefjes

V. M. E. Neefjes

Department of Paediatrics, Academic Hospital, University of Maastricht, Maastricht, and

Search for more papers by this author
W. W. M. Hack

W. W. M. Hack

Department of Paediatrics, Medical Centre Alkmaar, Alkmaar, The Netherlands

Search for more papers by this author
D. Roos

D. Roos

Central Laboratory of the Netherlands Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam,

Search for more papers by this author
First published: 24 December 2001
Citations: 32
D. Roos PhD, Central Laboratory of the Netherlands Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.  E-mail: [email protected]

Abstract

Chronic granulomatous disease (CGD) is a clinical syndrome of recurrent bacterial and fungal infections caused by a rare disorder of phagocytic cells. In CGD, the phagocytes are unable to generate oxygen radicals after stimulation of these cells, due to a defect in the NADPH oxidase system. This NADPH oxidase is a multicomponent enzyme of at least four subunits, of which the β-subunit of cytochrome b558, gp91-phox, is encoded by an X-linked gene (called CYBB). We report here five patients from two families; in each family we found a different mutation in the promoter region of CYBB. Both mutations prevented the expression of gp91-phox in the patients' neutrophils and thus caused inability of these cells to generate oxygen radicals. However, the mutations left the gp91-phox expression and the function of the NADPH oxidase in the patients' eosinophils intact. The relatively mild course of the CGD in these patients can probably be attributed to the fact that the eosinophils have retained their oxidative capacity. Furthermore, our results indicate that neutrophils and eosinophils differ in their regulation of gp91-phox expression.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.